01-04-26
AP3 Rec'd PCT/PTO 3 JAN 2006

PCT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/550,313	
	Filing Date	September 22, 2005	
	First Named Inventor	Eldridge et al	
	Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	9	Attorney Docket Number	AM-101319

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	31-documents	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	8 pp. International Search Report	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
Customer No. 38199			
Express Mail No. EQ013089908US			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	HOWSON AND HOWSON		
Signature	<i>Mary E. Bak</i>		
Printed name	Mary E. Bak		
Date	January 3, 2006	Reg. No.	31,215

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



AM-101319

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/550,313 Confirmation No.: 8349
Applicant : Eldridge et al.
Filed : September 22, 2005
TC/A.U. : unassigned
Examiner : unassigned
Customer No. : 38199
Title : IMMUNOGENIC COMPOSITION AND METHODS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Forms PTO/SB/08A/B are attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

REMARKS

Listed below are documents cited in the International Search Report dated October 8, 2004 in the corresponding International Patent Application No. PCT/US2004/006089, filed March 23, 2004. A copy of the Report is enclosed, together with copies of these documents.

- (BW) SUTTER et al., "Novel Vaccine Delivery Systems: Solutions to HIV Vaccine Dilemmas?", AIDS, 15(S): S139-S145 (2001)
- (BX) ROSE NINA et al., "An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants", Cell, 106(5): 539-549 (September 7, 2001)
- (BY) EGAN et al., "The Use of Cytokines and Chemokines as Genetic Adjuvants for Plasmid DNA Vaccines", Clin. Appl. Immunol. Rev., 2(4-5):255-287 (2002)
- (AV) EO et al., "Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules", J. Immunol., 166(9): 5473-5479 (May 1, 2001)
- (BZ) SHIVER et al., "Replication-Incompetent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency-Virus Immunity", Nature, 415:331-335 (February 17, 2002)
- (BBR) HAGLUND et al., "High-Level Primary CD8+ T-Cell Response to Human Immunodeficiency Virus Type I Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis Viruses", J. Virol., 76(6): 2730-2738 (March, 2002)
- (AL) International Patent Publication No. WO-96/34625-A, published November 7, 1996
- (BBS) ROBERTS et al., "Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors", J. Virol., 73(5): 3723-3732 (May, 1999)
- (AM) International Patent Publication No. WO-02/097091-A, published December 5, 2002.


The month of publication for documents AR, BW, and BY could not be determined. The years of publication for documents AR and BW are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not in issue (MPEP 609).

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (07-05)
Approved for use through 07/30/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/550,313
				Filing Date	September 22, 2005
				First Named Inventor	Eldridge et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	1	of	5	Attorney Docket Number	AM-101319

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,210,663	04-03-2001	ERTL	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-96/34625-A	11-07-1996	ROSE et al.		
	AM	WO-02/097091-A	12-05-2002	BARBER et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by Translation is attached. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/550,313
				Filing Date	September 22, 2005
				First Named Inventor	Eldridge et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	2	of	5	Attorney Docket Number	AM-101319

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	XIANG et al., "Genetic Vaccines, - A Revolution in Vaccinology?", Springer Semin. Immunopathol., 19(2): 257-268 (1997)	
	AS	SCHNEIDER et al., "Enhanced Immunogenicity for CD8+ T Cell Induction and Complete Protective Efficacy of Malaria DNA Vaccination by Boosting with Modified Vaccinia Virus Ankara", Nat. Med., 4(4): 397-402 (April, 1998)	
	AT	SEDEGAH et al., "Boosting with Recombinant Vaccinia Increased Immunogenicity and Protective Efficacy of Malaria DNA Vaccine", Proc. Natl. Acad. Sci., USA, 95: 7648-7653 (June, 1998)	
	AU	ROGERS et al., "Multistage Multiantigen Heterologous Prime Boost Vaccine for Plasmodium knoesi Malaria Provides Partial Protection in Rhesus Macaques", Infect. and Immunol., 69(9): 5565-5572 (September, 2001)	
	AV	EO et al., "Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules", J. Immunol., 166(9): 5473-5479 (May 1, 2001)	
	AW	RAMSHAW et al., "The Prime-Boost Strategy: Exciting Prospects for Improved Vaccination", Immunol. Today, 21(4): 163-165 (April, 2000)	
	AX	HANKE et al., "Development of a DNA-MVA/HIV A Vaccine for Kenya", Vaccine, 20(15): 1995-1998 (May 6, 2002)	
	AY	AMARA et al., "Control of Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine", Vaccine, 20(15): 1949-1955 (May, 2002)	
	AZ	WEE et al., "A DNA/MVA-Based Candidate Human Immunodeficiency Virus Vaccine for Kenya Induces Multi-Specific T Cell Response in Rhesus Macaques", J. General Virology, 83:75-80 (January, 2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/550,313
				Filing Date	September 22, 2005
				First Named Inventor	Eldridge et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	3	of	5	Attorney Docket Number	AM-101319

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	AAR	AMARA et al., "Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine", Science, 292(5514):69-74 (April 6, 2001)		
	AAS	MESEDA et al., "Prime-Boost Immunization with DNA and Modified Vaccinia Virus Ankara Vectors Expressing Herpes Simplex Virus-2 Glycoprotein D Elicits Greater Specific Antibody and Cytokine Responses than DNA Vaccine Alone", J. Infect. Dis., 186(8):1065-73 (October 15, 2002)		
	AAT	AMARA et al., "Different Patterns of Immune Responses by Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines", J. Virol., 76(15):7625-7631 (August, 2002)		
	AAU	GONZALO et al., "A Heterologous Prime-Boost Regime Using DNA and Recombinant Vaccinia Virus Expressing the Leishmania infantum P36/LACK Antigen Protects BALB/c Mice from Cutaneous Leishmaniasis", Vaccine, 20(7-8):1226-31 (January 15, 2002)		
	AAV	SCHNEIDER et al., "A Prime-Boost Immunisation Regimen Using DNA Followed by Recombinant Modified Vaccinia Virus Ankara Induces Strong Cellular Immune Responses Against the Plasmodium Falciparum TRAP antigen in Chimpanzees", Vaccine, 19(32):4595-602 (September 14, 2001)		
	AAW	HEL et al., "Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4 ⁺ and CD8 ⁺ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime-Boost Regimen", J. Immunol, 167: 7180-7191 (December 15, 2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.